Routine compliance certificate for Q2 FY27 dematerialization

Compliance View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹1.70

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.0%-0.6% vs market

Pharmaceuticals peers, median of 173sector-0.7%+0.1% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.0-0.6-0.7+0.1

Next day

+1.8+1.3+0.4+0.6+1.2

+2.4+1.1+1.3+0.3+2.0

+0.6-1.7+2.3-2.3+2.9

-0.6-1.4+0.9-2.1+1.5

+2.9-0.6+3.6-2.5+5.5

-1.2+0.3-1.5-2.5+1.4

15d

-8.2-6.1-2.1-4.3-4.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivanza Biosciences filed a routine SEBI compliance certificate for the quarter ended 30 September 2026 from its Registrar and Share Transfer Agent, Purva Sharegistry. The certificate confirms that 300 shares held by one shareholder were dematerialized and the physical certificates were cancelled within the prescribed timeline. This is a standard quarterly regulatory filing, not a material corporate event.

Likely market impact

No material impact. This is a routine quarterly compliance filing with no effect on operations or share price.